Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
semaxanib · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| fluorouracil | DRUG | - |
| leucovorin calcium | DRUG | - |
| semaxanib | DRUG | - |
DISEASE CHARACTERISTICS: Histologically confirmed, newly diagnosed or recurrent, metastatic colorectal cancer Primary disease was adenocarcinoma of the colon or rectum Bidimensionally measurable or evaluable disease No CNS metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECO...
Top 20 of 77 competitors
Semaxanib is an investigational small molecule being studied for the treatment of sarcoma and colorectal cancer. It was evaluated in clinical trials for AIDS-related Kaposi's sarcoma and metastatic colorectal cancer. The drug is still in clinical development and has not been approved by the FDA.
Semaxanib is being developed by Pfizer, Inc., which trades under the ticker symbol PFE on the New York Stock Exchange. The company sponsored clinical trials of the drug in patients with sarcoma and colorectal cancer.
Semaxanib has been studied in Phase 1 and Phase 3 clinical trials. One Phase 3 trial in metastatic colorectal cancer has been completed, and one Phase 1 trial in AIDS-related Kaposi's sarcoma has also been completed. The drug remains investigational and is not FDA approved.
Semaxanib has been studied in two completed clinical trials. NCT00003720 was a Phase 1 trial in patients with AIDS-related Kaposi's sarcoma, and NCT00004252 was a Phase 3 trial of leucovorin and fluorouracil with or without semaxanib in patients with metastatic colorectal cancer.
Yes, semaxanib is also known as SU5416. Clinical trial records refer to the drug as SU5416, including the Phase 1 trial in AIDS-related Kaposi's sarcoma and the Phase 3 trial in metastatic colorectal cancer.